Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Assets (2016 - 2025)

BioCorRx (BICX) has disclosed Assets for 16 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • Quarterly Assets rose 456.36% to $2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Dec 2025, up 456.36% year-over-year, with the annual reading at $2.1 million for FY2025, 456.36% up from the prior year.
  • Assets hit $2.1 million in Q4 2025 for BioCorRx, down from $7.5 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $7.5 million in Q3 2025 to a low of $317444.0 in Q1 2024.
  • Historically, Assets has averaged $1.9 million across 5 years, with a median of $819612.0 in 2021.
  • Biggest five-year swings in Assets: crashed 59.24% in 2022 and later skyrocketed 2042.45% in 2025.
  • Year by year, Assets stood at $819975.0 in 2021, then dropped by 6.51% to $766594.0 in 2022, then crashed by 49.27% to $388887.0 in 2023, then decreased by 0.76% to $385941.0 in 2024, then soared by 456.36% to $2.1 million in 2025.
  • Business Quant data shows Assets for BICX at $2.1 million in Q4 2025, $7.5 million in Q3 2025, and $6.7 million in Q2 2025.